Stroke Treatments

Find Stroke Treatments

Generic Name

Apixaban

Brand Names

Eliquis, Eliquis 30-Day

FDA approval date: December 28, 2012

Classification: Factor Xa Inhibitor

Form: Tablet, Kit

What is Eliquis (Apixaban)?

ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine...

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This study is researching an experimental drug called REGN7508 (called study drug). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other r...

PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism

Enrollment Status: Recruiting

Publish Date: June 10, 2026

Intervention Type: Drug, Device

Study Phase: Not Applicable

Summary: This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.

View All Clinical Trials